However, in a small phase II clinical trial of 16 NSCLC patients with KRAS G12D mutation, bortezomib showed only a modest disease control rate of 40%, only 1 objective response (ORR 6%), and a PFS of 1 month [92]. Here, KRAS is linked to non-small cell lung carcinoma.